Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.32−0.18 (-2.12%)
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
Ginkgo Bioworks operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ginkgo Bioworks's operating cash flow for the twelve months ending Jun 30, 2026 was -$170.24M. For fiscal 2025 it was -$171.06M. The highest annual figure on record is -$44.66M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$171.06M | – |
| FY2024 | Dec 31, 2024 | -$319.59M | – |
| FY2023 | Dec 31, 2023 | -$295.50M | – |
| FY2022 | Dec 31, 2022 | -$252.20M | – |
| FY2021 | Dec 31, 2021 | -$253.82M | – |
| FY2020 | Dec 31, 2020 | -$135.83M | – |
| FY2019 | Dec 31, 2019 | -$44.66M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$51.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$42.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$103.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$84.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$89.26M | – |
| Q4 FY2023 | Dec 31, 2023 | -$57.83M | – |
| Q3 FY2023 | Sep 30, 2023 | -$73.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$73.53M | – |
| Q1 FY2023 | Mar 31, 2023 | -$90.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$104.53M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$99.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$165.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$48.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$59.34M | – |
See a number that looks wrong?